Genfit SA
PAR:GNFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Saab AB
STO:SAAB B
|
SE |
|
T
|
Topsec Technologies Group Inc
SZSE:002212
|
CN |
|
V
|
Value HR Co Ltd
TSE:6078
|
JP |
|
Ifa Systems AG
XETRA:IS8
|
DE |
|
Ekopak NV
XBRU:EKOP
|
BE |
|
Industrivarden AB
STO:INDU A
|
SE |
|
R
|
Royal Century Resources Holdings Ltd
HKEX:8125
|
HK |
|
Sok Marketler Ticaret AS
IST:SOKM.E
|
TR |
|
Bright Health Group Inc
NYSE:NEUE
|
US |
|
F
|
Flair Writing Industries Ltd
NSE:FLAIR
|
IN |
|
Y
|
Yenher Holdings Bhd
KLSE:YENHER
|
MY |
|
D
|
Dream Residential Real Estate Investment Trust
TSX:DRR.U
|
CA |
|
N
|
Neurizer Ltd
ASX:NRZ
|
AU |
|
Bicicletas Monark SA
BOVESPA:BMKS3
|
BR |
|
Adani Power Ltd
NSE:ADANIPOWER
|
IN |
Genfit SA
Total Equity
Genfit SA
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genfit SA
PAR:GNFT
|
Total Equity
-€22.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Equity
€106.2m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Inventiva SA
PAR:IVA
|
Total Equity
-€8.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Total Equity
$75.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-12%
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Equity
$168.8m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-6%
|
|
|
Abivax SA
PAR:ABVX
|
Total Equity
€40.6m
|
CAGR 3-Years
78%
|
CAGR 5-Years
54%
|
CAGR 10-Years
-5%
|
|
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
See Also
What is Genfit SA's Total Equity?
Total Equity
-22.5m
EUR
Based on the financial report for Dec 31, 2025, Genfit SA's Total Equity amounts to -22.5m EUR.
What is Genfit SA's Total Equity growth rate?
Total Equity CAGR 5Y
-7%
